• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 23, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

St18 is a negative regulator of VEGF

Bioengineer by Bioengineer
July 15, 2020
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Kenta Maruyama

Various pro-inflammatory cytokines and pathogen-associated molecular patterns such as lipopolysaccharide (LPS) are known to activate NF-kB. NF-kB is a master regulator of inflammation and induces pro-inflammatory cytokines. Although LPS-induced pro-inflammatory cytokiens are indispensable for host defense against pathogens, dysregulated production can lead to septic shock. Septic shock is the most common cause of death in intensive care unit. Pro-inflammatory cytokines in a systemic scale inflammatory response result in increased capillary permeability and low blood pressure. However, despite injection of anti-pro-inflammatory cytokine antibody into human septic shock, mortality rates remain high. Other than pro-inflammatory cytokines, macrophages can secrete vascular endothelial growth factor (VEGF) in response to LPS. VEGF was initially described as a stimulator of endothelial permeability. VEGF was subsequently reported to promote proliferation and survival of endothelial cells, and is now thought to be the pivotal regulator of angiogenesis and vascular leakage. Notably, VEGF exaggerates septic inflammation, and human serum VEGF level can be used as a predictor of septic prognosis. Thus, not only pro-inflammatory cytokines but also VEGF play critical roles for septic pathophysiology. Recently, Suppression of tumorigenicity 18 (St18) was discovered as a putative regulator of pro-inflammatory cytokine signaling. St18 is also reported as a candidate tumor suppressor in human breast tumors, because its expression is significantly down regulated in these cells compared to normal breast tissues. Conversely, St18 expression is up regulated in liver cancers, indicating an oncogenic function of this gene. Despite the pleiotropic functions of St18 in cancers, little is known about its functions in myeloid lineages. Maruyama and colleagues discovered that St18 is expressed in myeloid cells. Unexpectedly, mice lacking St18 in myeloid lineages exhibit increased retinal vasculature with enhanced serum VEGF concentrations, and pharmacological inhibition of VEGF signaling rescued the high mortality rate of septic shock. Mechanistically, St18 bound to Sp1 and attenuated its activity, leading to the suppression of Sp1 target gene VEGF. Thus, myeloid St18-mediated gene regulation may be a promising strategy for the development of therapeutics to control VEGF-associated disorders.

###

Media Contact
Kenta maruyama
[email protected]

Original Source

https://www.cell.com/cell-reports/fulltext/S2211-1247(20)30887-1

Related Journal Article

http://dx.doi.org/10.1016/j.celrep.2020.107906

Tags: cancerCell BiologyMedicine/HealthMolecular BiologyPhysiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

August 23, 2026

ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

August 23, 2026

Tirzepatide Versus GLP-1 Agonists for Stroke Risk in Atrial Fibrillation and Diabetes

August 22, 2026

Real-world study examines psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions in 198 patients

August 22, 2026
Please login to join discussion

POPULAR NEWS

  • Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

    29 shares
    Share 12 Tweet 7
  • ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

    29 shares
    Share 12 Tweet 7
  • KAIST Surface Defects Boost Droplet Formation, Removal, and Heat Transfer by 5.5-Fold

    29 shares
    Share 12 Tweet 7
  • Dual-oxygen pancreatic cancer organoids mirror basal-classical diversity, spatial transcriptomics confirms

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

KAIST Surface Defects Boost Droplet Formation, Removal, and Heat Transfer by 5.5-Fold

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.